BAM15 10mg: What Researchers Need to Know in 2026
Mitochondrial uncouplers have fascinated metabolic researchers for decades — and for good reason. The ability to make cells burn more energy without additional movement represents one of the most mechanistically elegant approaches to fat loss ever studied. BAM15 has emerged as the compound that may finally make this approach viable, offering the energy-dissipating power of older uncouplers without the safety ceiling that made them unusable.
Here is a structured overview of what the current research says about BAM15, how it compares to prior uncouplers, and what researchers and curious readers should understand before diving deeper.
What Is BAM15?
BAM15 (also referred to as BAM15-2) is a small-molecule mitochondrial proton carrier — a type of compound known as a mitochondrial uncoupler. It works by shuttling protons across the inner mitochondrial membrane, bypassing the ATP synthase enzyme. The result: mitochondria burn fuel (glucose and fat) but produce heat instead of ATP.
What distinguishes BAM15 from older uncouplers like 2,4-dinitrophenol (DNP) is its selectivity. DNP is membrane-permeable at virtually any concentration, which makes it dangerously dose-sensitive — researchers and the general public learned this the hard way throughout the 20th century. BAM15 was developed specifically to decouple fat burning from the systemic toxicity profile that made DNP a dead end.
Crucially, BAM15 appears to be mitochondrial membrane-selective, meaning it does not substantially depolarize the plasma membrane at research-relevant concentrations. It also does not appear to raise core body temperature in animal models at effective doses — one of DNP’s most dangerous effects.
Research Overview
The landmark study on BAM15 was published in Nature Communications in 2020 by Kenwood et al. The paper — titled “BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control” — demonstrated that BAM15 reduced fat mass in diet-induced obese mice without reducing food intake, without loss of lean mass, and without increasing core body temperature.
Additional research published via PubMed (PMID: 32424128) corroborates these metabolic findings, showing improvements in insulin sensitivity and reductions in liver fat (hepatic steatosis), positioning BAM15 as a candidate for research in metabolic syndrome, NAFLD, and type 2 diabetes models.
A 2022 follow-up study explored BAM15’s role in reducing reactive oxygen species (ROS) and improving mitochondrial efficiency, suggesting the compound may have secondary benefits in oxidative stress contexts beyond just energy balance. Discussion of this research continues actively on forums like r/Peptides on Reddit, where researchers share anecdotal observations alongside citations.
Potential Benefits Studied
- Reduction in adipose (fat) mass — demonstrated in rodent obesity models without caloric restriction
- Preservation of lean muscle mass — unlike traditional weight-loss interventions, BAM15 in studies did not cause muscle catabolism
- Improved insulin sensitivity — rodent data show meaningful improvements in glucose tolerance
- Reduction in hepatic fat — relevant to NAFLD and metabolic syndrome research models
- Mitochondrial ROS reduction — mild uncoupling may reduce oxidative stress at the cellular level
- No core temperature elevation at effective doses — a key differentiator from DNP and older uncouplers
- No appetite suppression required — energy expenditure mechanism is independent of satiety signaling
Dosage & Administration
All dosing information below pertains to preclinical research models only. BAM15 has not been approved for human use by the FDA or any equivalent regulatory body, and no standardized human dosing protocol exists.
In rodent studies, BAM15 has been administered orally at doses ranging from approximately 25 mg/kg to 50 mg/kg body weight. These doses are not directly translatable to human equivalents using simple bodyweight math — human equivalent dose (HED) calculations using FDA conversion factors produce substantially lower numbers, but these remain speculative in the absence of human pharmacokinetic data.
BAM15 10mg capsules, as found in research supply contexts, are intended for in vitro and in vivo laboratory research. Researchers working with this compound should consult appropriate IACUC protocols and institutional guidelines when designing experiments.
Half-life data in rodents suggests BAM15 has a relatively short active window, supporting multiple-dosing research protocols rather than single large-dose designs. Solubility in DMSO and aqueous suspension vehicles has been documented in published protocols.
Where to Find BAM15 for Research
Researchers sourcing BAM15 for laboratory use can find BAM15 10mg available at combatresearch.is. Combat Research supplies compounds for research purposes and operates with a focus on compound integrity and third-party verification.
Conclusion
BAM15 represents a meaningful step forward in mitochondrial uncoupler research. Where DNP offered a mechanism that worked but came with an unacceptable safety profile, BAM15 appears to decouple the thermogenic and metabolic benefits from the toxicity. The 2020 Nature Communications study alone is compelling enough to warrant serious attention from metabolic researchers, and subsequent data on ROS reduction only widens its potential research applications.
Whether BAM15 will eventually make the leap to clinical development for obesity or metabolic disease remains to be seen — but as a research tool, it is one of the more scientifically grounded compounds in the mitochondrial biology space right now.
Disclaimer: This article is intended for educational and research purposes only. BAM15 is not approved by the FDA for human use. Nothing in this article constitutes medical advice, a treatment recommendation, or an endorsement of human use. Always consult a qualified medical professional before making any health-related decisions. Combat Research products are sold strictly for laboratory and research use.
